Metabolic syndrome: a high-cardiovascular risk
Pan, C.-Y.; Cheng, Y.
Zhonghua Nei Ke Za Zhi 43(11): 801-802
2004
ISSN/ISBN: 0578-1426 PMID: 15634533 Document Number: 571311
Document emailed within 1 workday
Related Documents
Charbonnel, B. 2005: Metabolic syndrome and cardiovascular risk La Revue du Praticien 55(16): 1765-1771Fiuza, M.; Cortez-Dias, N.; Martins, S.; Belo, A.; Dias, A.D.C.; Neves, A.S.; Frazão, A.é; Pereira, A.ón.A.P.; Do Vale, A.ón.F.M.; Dias Simas, A.M.; Estrela, C.; Amorim, E.A.; Almeida, F.E.M.; Amaral, G.M.B.; Silva, I.M.S.; Sousa, J.M.M.; Morgado, J.M.O.; Santos, J.é C.O.; Senra, J.é F.M.; Amaral, L.G.M.; Aleixo, L.G.; Soares, L.M.S.; Cafede, M.C.F.A.; Colleo, M.O.M.C.; Senra, M.C.M.; Ramiro, M.J.R.C.C.; Borges, M.M.S.A.P.; Amaral, P.N.P.; Andrade, R.M.L.; Costa, R.P.D.R.C.; Conde, A.I.; Rodrigues, A.; Santana, A.; Morais, A.S.; Cardoso, A.A.M.V.; Barros, A.; Perez, A.; Matias, A.; Carina, A.; Cardoso, A.M.C.S.E.; Dinis, A.R.F.; Santana, A.; Baltazar, A.; Vieira, A.ón.J.é C.; Farias, A.M.; Martins, A.V.; Magalhães, A.M.B.; Graça,; 2008: Metabolic syndrome in Portugal: prevalence and implications for cardiovascular risk--results from the VALSIM Study Revista Portuguesa de Cardiologia: Orgao Oficial da Sociedade Portuguesa de Cardiologia 27(12): 1495-1529
Glasser, S.P. 2001: Hypertension syndrome and cardiovascular events. High blood pressure is only one risk factor Postgraduate Medicine 110(5): 29-36
Volf, E.M.; Levine, D.E.; Michelon, M.A.; Au, S.-C.; Patvardhan, E.; Dumont, N.; Loo, D.S.; Kuvin, J.; Gottlieb, A.B. 2011: Assessor-blinded study of the metabolic syndrome and surrogate markers of increased cardiovascular risk in children with moderate-to-severe psoriasis compared with age-matched population of children with warts Journal of Drugs in Dermatology: Jdd 10(8): 900-901
Cheung, L.P.; Ma, R.C.W.; Lam, P.M.; Lok, I.H.; Haines, C.J.; So, W.Y.; Tong, P.C.Y.; Cockram, C.S.; Chow, C.C.; Goggins, W.B. 2008: Cardiovascular risks and metabolic syndrome in Hong Kong Chinese women with polycystic ovary syndrome Human Reproduction 23(6): 1431-1438
Sánchez-Torres, R.J.; Delgado-Osorio, H.éc. 2005: The metabolic syndrome and its cardiovascular manifestations Boletin de la Asociacion Medica de Puerto Rico 97(4): 271-280
Vitarius, J.A. 2005: The metabolic syndrome and cardiovascular disease Mount Sinai Journal of Medicine new York 72(4): 257-262
Os, I.; Hjermann, I.; Nordby, G. 1991: Hypertension as a part of metabolic cardiovascular syndrome Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 111(25): 3062-3064
Zeman, M.; Zák, A.; Vecka, M.; Tvrzická, E. 2005: Insulin resistance, metabolic syndrome and cardiovascular diseases Casopis Lekaru Ceskych 144(Suppl 1): 19-20; 22-26
Bano, K.A.; Batool, A. 2007: Metabolic syndrome, cardiovascular disease and type-2 diabetes JPMA. Journal of the Pakistan Medical Association 57(10): 511-515
Guo, L.; Hu, X-shu.; Guo, Z-rong.; Kang, G-dong.; Wu, M.; Zhou, H. 2009: Association and interaction between the components of metabolic syndrome and cardiovascular disease Zhonghua Xin Xue Guan Bing Za Zhi 37(7): 644-647
Vuletić, S.; Kern, J.; Ivanković, D.; Polasek, O.; Brborović, O. 2007: Metabolic syndrome in the Croatian population--the multiple cardiovascular risks Acta Medica Croatica: Casopis Hravatske Akademije Medicinskih Znanosti 61(3): 239-243
Kozłowska, A.; Kowalska, I. 2006: The role of adiponectin in pathogenesis of metabolic syndrome and cardiovascular disease Endokrynologia Polska 57(6): 626-632
Soares, G.M.; Vieira, C.S.; de Paula Martins, W.; Dos Reis, R.M.; de Sá, M.F.S.; Ferriani, R.A. 2009: Metabolic and cardiovascular impact of oral contraceptives in polycystic ovary syndrome International Journal of Clinical Practice 63(1): 160-169
Ford, E.S. 2005: Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence Diabetes Care 28(7): 1769-1778
De Castro, J.; Van de Water, A.; Wouters, L.; Xhonneux, R.; Reneman, R.; Kay, B. 1979: Comparative study of cardiovascular, neurological and metabolic side effects of 8 narcotics in dogs. Pethidine, piritramide, morphine, phenoperidine, fentanyl, R 39 209, sufentanil, R 34 995. III. Comparative study of the acute metabolic toxicity of the narcotics used in high and massive doses in curarised and mechanically ventilated dogs Acta Anaesthesiologica Belgica 30(1): 71-90
Bognounou, R.; Diendéré, A.; Diallo, I.; Tieno, H.; Guira, O.; Ouedraogo, D.D.; Drabo, Y.J. 2011: Metabolic disorders and cardiovascular risk factors observed in patients infected by the HIV with antiretroviral therapy in Burkina Faso Medecine Tropicale: Revue du Corps de Sante Colonial 71(6): 626-627
Káli, A.ás.; Jánosi, A.ás. 2006: Endothelial function in high risk cardiovascular patients Orvosi Hetilap 147(3): 99-106
Richard, J.L.; Delahaye, F. 1998: Cardiovascular prevention, primary or secondary, in high risk patients Archives des Maladies du Coeur et des Vaisseaux 91(12): 1495-1502
Moulin, P.; Sérusclat, Aé.; Bernard, S. 2005: Cardiovascular prevention of high risk patients by hypolipidemic treatment La Revue du Praticien 55(16): 1783-1787